Japan· JP-1249010D1025
チザニジン塩酸塩
A tizanidine product containing チザニジン塩酸塩, registered in Japan by サンファーマ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Tizanidine is registered in 14 of 19 countries.
Countries holding a registration under ATC M03BX02 (tizanidine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Tizanidine · ATC M03BX02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tizanidine costs, country by country.
Normalised to the WHO defined daily dose (12 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tizanidine · price per daily dose (12 mg)
USD · FX 28 Sept 2026
- CH Switzerland$2.38
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- チザニジン塩酸塩
- Manufacturer
- サンファーマ
- Country
- Japan (JP)
- ATC code
- M03BX02
- ATC class
- Tizanidine
- Defined daily dose
- 12 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
384 interactions on record for tizanidine.
Graded by severity as the source publishes them — 78 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tizanidine · interactions on record
384 records
- 78 severe
- 177 moderate
- 2 minor
- 87 info
Most severe, free to view
- CimetidineA02BA01severe
- FamotidineA02BA03severe
- PapaverineA03AD01severe
- CisaprideA03FA02severe
40 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M03BX02
Tizanidine, as other registers publish it.
- CanadaAPO-TIZANIDINEAPOTEX INC
- PolandChordynaBausch Health Ireland Ltd.
- PolandChordynaBausch Health Ireland Ltd.
- NetherlandsChordyna 2 mg, tablettenBausch Health Ireland Limited
- NetherlandsChordyna 4 mg, tablettenBausch Health Ireland Limited
- CanadaMINT-TIZANIDINEMINT PHARMACEUTICALS INC
- PolandNavizanZakłady Farmaceutyczne POLPHARMA S.A.
- PolandNavizanZakłady Farmaceutyczne POLPHARMA S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9229e81-221a-416c-9298-8d8e6c60cc22 GET /v1/drugs/e9229e81-221a-416c-9298-8d8e6c60cc22?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．２％１ｇ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1249010D1025",
"category": "内用薬",
"price_yen": 17.7,
"generic_name": "チザニジン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1249",
"transitional_expiry": null
}See everything about tizanidine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.